NPCE

Company Overview — What Does NeuroPace Inc Do?

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California. NeuroPace Inc (NPCE) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael Favet and employs approximately 170 people. With a market capitalization of $474M, NPCE is one of the notable companies in the Healthcare sector.

NeuroPace Inc (NPCE) Stock Rating — Reduce (April 2026)

As of April 2026, NeuroPace Inc receives a Reduce rating with a composite score of 37.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NPCE ranks #2,008 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NeuroPace Inc ranks #216 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NPCE Stock Price and 52-Week Range

NeuroPace Inc (NPCE) currently trades at $14.26. The stock lost $0.39 (2.7%) in the most recent trading session. The 52-week high for NPCE is $18.98, which means the stock is currently trading -24.8% from its annual peak. The 52-week low is $7.56, putting the stock 88.6% above its annual trough. Recent trading volume was 123K shares, suggesting relatively thin trading activity.

Is NPCE Overvalued or Undervalued? — Valuation Analysis

NeuroPace Inc (NPCE) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 25.67x, versus the sector average of 2.75x. The price-to-sales ratio is 5.17x, compared to 1.66x for the average Healthcare stock.

At current multiples, NeuroPace Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NeuroPace Inc Profitability — ROE, Margins, and Quality Score

NeuroPace Inc (NPCE) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -127.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -22.9% versus the sector average of -33.1%.

On a margin basis, NeuroPace Inc reports gross margins of 76.2%, compared to 71.5% for the sector. The operating margin is -20.4% (sector: -66.1%). Net profit margin stands at -26.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 42.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NPCE Debt, Balance Sheet, and Financial Health

NeuroPace Inc has a debt-to-equity ratio of 455.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 5.28x, indicating strong short-term liquidity. Total debt on the balance sheet is $59M. Cash and equivalents stand at $21M.

NPCE has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NeuroPace Inc is 40/100, reflecting average volatility within the normal range for its sector.

NeuroPace Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, NeuroPace Inc reported revenue of $94M and earnings per share (EPS) of $-0.66. Net income for the quarter was $-24M. Gross margin was 76.2%. Operating income came in at $-19M.

In FY 2025, NeuroPace Inc reported revenue of $100M and earnings per share (EPS) of $-0.66. Net income for the quarter was $-21M. Gross margin was 77.2%. Revenue grew 25.1% year-over-year compared to FY 2024. Operating income came in at $-16M.

In Q3 2025, NeuroPace Inc reported revenue of $27M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-3M. Gross margin was 77.4%. Revenue grew 29.9% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, NeuroPace Inc reported revenue of $24M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-9M. Gross margin was 77.1%. Revenue grew 22.1% year-over-year compared to Q2 2024. Operating income came in at $-7M.

Over the past 8 quarters, NeuroPace Inc has demonstrated a growth trajectory, with revenue expanding from $19M to $94M. Investors analyzing NPCE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NPCE Dividend Yield and Income Analysis

NeuroPace Inc (NPCE) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NPCE Momentum and Technical Analysis Profile

NeuroPace Inc (NPCE) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

NPCE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NeuroPace Inc (NPCE) ranks #216 out of 838 stocks based on the Blank Capital composite score. This places NPCE in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NPCE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NPCE vs S&P 500 (SPY) comparison to assess how NeuroPace Inc stacks up against the broader market across all factor dimensions.

NPCE Next Earnings Date

No upcoming earnings date has been announced for NeuroPace Inc (NPCE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NPCE? — Investment Thesis Summary

The quantitative profile for NeuroPace Inc suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 29/100 indicates premium valuation.

In summary, NeuroPace Inc (NPCE) earns a Reduce rating with a composite score of 37.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NPCE stock.

Related Resources for NPCE Investors

Explore more research and tools: NPCE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NPCE head-to-head with peers: NPCE vs AZN, NPCE vs SLGL, NPCE vs VMD.